胸腺瘤型重症肌无力胸腺切除术后长期神经缓解的预测因素:多机构数据库分析
该多机构数据库研究纳入193例2000至2013年间手术切除的胸腺瘤型重症肌无力患者,评估胸腺切除术后完全稳定缓解(CSR)和复合神经缓解(CNR)的预测因素。10年CSR和CNR累积概率分别为36.9%和69.1%。术前症状轻微是CSR的显著预测因素(P=0.040),大肿瘤是CNR的预测因素(P<0.001)。
要点
- 术前症状轻微预测完全稳定缓解(P=0.040)
- 大肿瘤预测复合神经缓解(P<0.001)
- 手术方式、胸腺瘤分期及组织学亚型与长期神经缓解无关
核心结论
- 大肿瘤尺寸和术前轻微症状是胸腺瘤型重症肌无力长期神经结局的预测因素。
- 对于症状轻微且早期发病、未接受免疫抑制治疗的胸腺瘤型重症肌无力患者,早期手术干预可能有利于控制神经结局。
研究设计与样本
- 多机构数据库回顾性分析,纳入193例2000至2013年间手术切除的胸腺瘤型重症肌无力患者(47.3±12.0岁;男:女=90:103)。
- 采用Cox回归分析评估完全稳定缓解(CSR)和复合神经缓解(CNR)的预测因素。
主要发现
- 重症肌无力至胸腺切除术的中位间期为3.1个月。
- 161例(83.4%)患者症状低于美国重症肌无力基金会临床分级III级。
- 所有患者接受扩大胸腺切除术,无围手术期死亡。
- 10年CSR和CNR累积概率分别为36.9%和69.1%。
- 术前轻微症状是CSR的显著预测因素(P=0.040),大肿瘤是CNR的预测因素(P<0.001)。
关键数值与推荐
- 大肿瘤患者与重症肌无力早发和未接受类固醇治疗相关。
- 手术方法、胸腺瘤分期和组织学亚型与长期神经缓解无关。
临床怎么用
- 对于症状轻微的胸腺瘤型重症肌无力患者,尤其是早发且未接受免疫抑制治疗者,应考虑早期手术干预以改善神经结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thymectomy is the treatment of choice for thymomatous myasthenia gravis (MG) for both oncological and neurological aspects. However, only a few studies comprising small numbers of patients have investigated post-thymectomy neurological outcomes. We examined post-thymectomy long-term neurological outcomes and predictors of thymomatous MG using a multi-institutional database. METHODS: In total, 193 patients (47.3 ± 12.0 years; male:female = 90:103) with surgically resected thymomatous MG between 2000 and 2013 were included. Complete stable remission (CSR) and composite neurological remission (CNR), defined as the achievement of CSR and pharmacological remission after thymectomy, were evaluated. Predictors for CSR and CNR were examined by Cox regression analysis. RESULTS: The median duration between MG and thymectomy was 3.1 months. In addition, 161 patients (83.4%) had symptoms less than Myasthenia Gravis Foundation of America clinical classification III. All patients underwent an extended thymectomy; there were no perioperative deaths. The 10-year cumulative probability of CSR and CNR was 36.9% and 69.1%, respectively. Mild preoperative symptoms were a significant predictor for CSR (P = 0.040), and a large tumour was a predictor for CNR (P < 0.001). Patients with a large tumour were associated with early MG onset and no steroid treatment. Surgical methods, thymoma stage and histological subtypes were not associated with long-term neurological remission. CONCLUSIONS: Large tumour size and preoperative mild symptoms were predictors for long-term neurological outcome in thymomatous MG. Considering that patients with early onset of MG and no immunosuppressive treatment tend to have large tumours, early surgical intervention for patients with thymomatous MG having mild symptoms might be beneficial for controlling neurological outcomes.
引用
- Na KJ, Hyun K, Kang CH, et al. Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: an analysis from a multi-institutional database. Eur J Cardiothorac Surg. 2020. PMID: 31859338. doi:10.1093/ejcts/ezz334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。